Respiratory Disease Management

Inhaler and Nebulizer Use

• For most patients with asthma or COPD, hand-held inhalers are the first-line delivery method for bronchodilator medications, while nebulizers should be reserved for specific situations such as severe exacerbations, inability to use inhalers properly, or when higher medication doses are required, according to the European Respiratory Society 1
• Nebulizers may be preferred for patients who cannot coordinate breathing with inhaler activation, or require higher medication doses, such as salbutamol >1 mg or ipratropium bromide >160-240 μg, as recommended by the European Respiratory Society 1
• The European Respiratory Society recommends first-line maintenance therapy for most patients with asthma and COPD using hand-held inhalers for doses up to 1 mg salbutamol or equivalent, and nebulized therapy with terbutaline 5-10 mg can be considered for maintenance therapy if higher doses are required 1
• In acute severe exacerbations, nebulizers may be used, and treatment may be repeated within minutes if response is suboptimal, as suggested by the European Respiratory Society 1
• Patients should transition to hand-held inhalers once condition stabilizes, and consider nebulizer only after optimizing inhaler therapy and if higher doses are needed, according to the European Respiratory Society 1

Dosage Recommendations

• The recommended adult dosage of terbutaline is 5-10 mg administered via nebulizer, and treatment may be repeated at 4-6 hour intervals based on response, as recommended by the European Respiratory Society 1
• The following table summarizes the recommended dosages:

2

• For mild symptoms, use short-acting bronchodilators such as salbutamol 200-400 μg or terbutaline 500-1000 μg four times daily via hand-held inhaler, with a strength of evidence supported by the British Thoracic Society 2, 3

Oxygen Therapy

• Evaluate the need for Long-Term Oxygen Therapy (LTOT) if PaO₂ <7.3 kPa with or without hypercapnia and FEV₁ <1.5 liters, or PaO₂ between 7.3-8.0 kPa with evidence of pulmonary hypertension, peripheral edema, or nocturnal hypoxemia, as recommended by the British Thoracic Society 3
• LTOT must be given for at least 15 hours daily via oxygen concentrator with nasal prongs, set at 2-4 L/min based on blood gas assessment, with a strength of evidence supported by the European Respiratory Society 3
• Ensure the patient has stopped smoking before prescribing LTOT, as recommended by the American Thoracic Society 3
• For patients with suspected or confirmed COPD, target oxygen saturation of 88-92% using a Venturi mask (24-28%) for controlled oxygen delivery, and use a nasal cannula for lower flow requirements, as recommended by the British Thoracic Society 2

Patient Education and Follow-up

• Patients should receive formal instruction in nebulizer use, with the first dose given under supervision, and be informed that nebulized therapy is for breakthrough symptoms or exacerbations, not regular use, as recommended by the British Thoracic Society 2
• Ensure proper nebulizer technique to avoid eye exposure to ipratropium, which can cause blurred vision or worsen glaucoma, and patients with glaucoma should use a mouthpiece rather than a face mask, as recommended by the British Thoracic Society 2
• Regular follow-up at a respiratory clinic is essential, with six-monthly follow-up and reassessment recommended for patients on LTOT, as suggested by the British Thoracic Society 2, 3